RWA
CYCN icon

Ropes Wealth Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Ropes Wealth Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79
Closed -$5K – 376
2020
Q4 		$5K Hold
79
– – ﹤0.01% 571
2020
Q3 		$10K Buy
+79
New +$9.03K ﹤0.01% 513

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ropes Wealth Advisors's CYCN Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 79 shares — an estimated $5K sold.

Ropes Wealth Advisors first reported a position in CYCN in Q3 2020 and held it in 2 quarters. The position peaked at $10K in Q3 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • Ropes Wealth Advisors reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Ropes Wealth Advisors sold 79 Cyclerion Therapeutics shares in Q1 2021, an estimated $5K.
  • Ropes Wealth Advisors first reported a position in Cyclerion Therapeutics in Q3 2020 and held it in 2 quarters.
  • Ropes Wealth Advisors's Cyclerion Therapeutics position peaked at $10K in Q3 2020.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.